Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives.

Galasso G, Schiekofer S, D'Anna C, Gioia GD, Piccolo R, Niglio T, Rosa RD, Strisciuglio T, Cirillo P, Piscione F, Trimarco B.

Angiology. 2014 Mar;65(3):180-9. doi: 10.1177/0003319712474336. Epub 2013 Jan 29. Review.

PMID:
23362304
2.

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction.

Gupta S, Gupta MM.

Indian Heart J. 2016 Jul-Aug;68(4):539-51. doi: 10.1016/j.ihj.2016.04.006. Epub 2016 Apr 19. Review.

3.

[Myocardial no-reflow phenomenon: recent knowledges].

Pontecorvo ML, Spaziani C, Montone RA, Cosentino N, Minelli S, Niccoli G.

Recenti Prog Med. 2011 Feb;102(2):53-7. Italian.

PMID:
21513120
4.

Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Buyukkaya E, Poyraz F, Karakas MF, Kurt M, Akcay AB, Akpinar I, Motor S, Turak O, Ozturk OH, Sen N, Akpek M, Kaya MG, Gibson CM.

Am J Cardiol. 2013 Jul 15;112(2):187-93. doi: 10.1016/j.amjcard.2013.03.011. Epub 2013 Apr 18.

PMID:
23601576
5.

Impact of coronary microvascular function on long-term cardiac mortality in patients with acute ST-segment-elevation myocardial infarction.

van de Hoef TP, Bax M, Meuwissen M, Damman P, Delewi R, de Winter RJ, Koch KT, Schotborgh C, Henriques JP, Tijssen JG, Piek JJ.

Circ Cardiovasc Interv. 2013 Jun;6(3):207-15. doi: 10.1161/CIRCINTERVENTIONS.112.000168. Epub 2013 Jun 4.

6.

Intracoronary injection of drugs to treat no--reflow phenomenon and microcirculatory dysfunction.

Rognoni A, Lupi A, Cavallino C, Secco GG, Rosso R, Bongo AS.

Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):84-8. Review.

PMID:
22973862
7.

Microvascular obstruction after primary percutaneous coronary intervention: pathogenesis, diagnosis and prognostic significance.

Niccoli G, Cosentino N, Minelli S, Cataneo L, Crea F.

Curr Vasc Pharmacol. 2013 Mar 1;11(2):245-62. Review.

PMID:
23506502
8.

Intracoronary ECG during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction predicts microvascular obstruction and infarct size.

Wong DT, Leung MC, Das R, Liew GY, Teo KS, Chew DP, Meredith IT, Worthley MI, Worthley SG.

Int J Cardiol. 2013 Apr 30;165(1):61-6. doi: 10.1016/j.ijcard.2011.07.078. Epub 2011 Aug 28.

PMID:
21875755
9.

Pathophysiology of the no-reflow phenomenon.

Vrints CJ.

Acute Card Care. 2009;11(2):69-76. doi: 10.1080/17482940902978061. Review.

PMID:
19526383
10.

Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.

Guo AQ, Sheng L, Lei X, Shu W.

J Int Med Res. 2013 Jun;41(3):537-47. doi: 10.1177/0300060513479859. Epub 2013 Apr 29. Review. Retraction in: J Int Med Res. 2014 Oct;42(5):1188.

PMID:
23628920
11.

Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.

Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D.

Am Heart J. 2006 Nov;152(5):887.e9-14.

PMID:
17070151
12.

Myocardial 'no-reflow'--diagnosis, pathophysiology and treatment.

Wong DT, Puri R, Richardson JD, Worthley MI, Worthley SG.

Int J Cardiol. 2013 Sep 1;167(5):1798-806. doi: 10.1016/j.ijcard.2012.12.049. Epub 2013 Jan 26. Review.

PMID:
23357047
13.

No-reflow phenomenon: maintaining vascular integrity.

Kloner RA.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):244-50. doi: 10.1177/1074248411405990. Review.

PMID:
21821523
14.

Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.

Eitel I, Nowak M, Stehl C, Adams V, Fuernau G, Hildebrand L, Desch S, Schuler G, Thiele H.

Am Heart J. 2010 May;159(5):882-90. doi: 10.1016/j.ahj.2010.02.019.

PMID:
20435200
15.

Management of the no-reflow phenomenon.

Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ.

Pharmacol Ther. 2011 Oct;132(1):72-85. doi: 10.1016/j.pharmthera.2011.05.010. Epub 2011 Jun 12. Review.

PMID:
21664376
16.

The reduction of infarct size--forty years of research.

Ferreira R.

Rev Port Cardiol. 2010 Jun;29(6):1037-53. Review. English, Portuguese.

17.

Coronary microvascular reperfusion injury and no-reflow in acute myocardial infarction.

Kang S, Yang Y.

Clin Invest Med. 2007;30(3):E133-45. Review.

PMID:
17716552
18.

Myocardial no-reflow in humans.

Niccoli G, Burzotta F, Galiuto L, Crea F.

J Am Coll Cardiol. 2009 Jul 21;54(4):281-92. doi: 10.1016/j.jacc.2009.03.054. Review.

19.

Reperfusion arrhythmias during coronary angioplasty for acute myocardial infarction predict ST-segment resolution.

Ilia R, Amit G, Cafri C, Gilutz H, Abu-Ful A, Weinstein JM, Yaroslavtsev S, Gueron M, Zahger D.

Coron Artery Dis. 2003 Sep;14(6):439-41.

PMID:
12966264
20.

The no-reflow phenomenon: State of the art.

Bouleti C, Mewton N, Germain S.

Arch Cardiovasc Dis. 2015 Dec;108(12):661-74. doi: 10.1016/j.acvd.2015.09.006. Epub 2015 Nov 23. Review.

Supplemental Content

Support Center